StreetAlpha.app
Home › Stocks › ALLR

Allarity Therapeutics, Inc. (ALLR)

$0.84
▼ −3.91%
LAST CLOSE · NOV 17

Allarity Therapeutics develops cancer treatments, mainly stenoparib, and a companion diagnostic test to identify patients likely to benefit from them. It last closed at $0.84 on Nov 17, down 3.91% on the day.

AI Auto Pilots
Is ALLR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$350K
Net income
−$15.7M
−4493.7% margin
EPS (diluted)
−$0.98
−110.8% vs a year ago
Free cash flow
−$13.2M
−3785.4% margin
Valuation
Market cap
$13.5M
16.0M shares
P/E
–
No P/E while losing money
Price to sales
38.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$14.1M
At Sep 30
Shareholder equity
−$2.3M
Buybacks
$746K
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$1.3M−$1.3MFY2021FY2024: $0$0FY2024FY2025: $320K$320KFY2025

From ALLR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ALLR in the past 90 days, not enough for a consensus
Average 12-month target
$11.25
▲ 1237.7% upside

Based on 1 analyst who set a price target on ALLR in the past 90 days. The average target is $11.25, with a high of $11.25 and a low of $11.25, compared with the last close of $0.84.

Low $11.25Avg $11.25High $11.25
Blue marker: last close $0.84
Highest target$11.25
Average target$11.25
Lowest target$11.25
Latest rating changes
Ascendiant CapitalTarget raised
Nov 17Buy$11 → $11.25
Ascendiant CapitalTarget raised
Sep 16Buy$10.25 → $11
Ascendiant CapitalMaintained
Jun 8Buy$10.25
DateFirmActionRatingPrice target
Nov 17Ascendiant CapitalTarget raisedBuy$11 → $11.25
Sep 16Ascendiant CapitalTarget raisedBuy$10.25 → $11
Jun 8Ascendiant CapitalMaintainedBuy$10.25
Loading…

Technical Analysis

ALLR · as of the Nov 17 close · updated after every close
Downtrend

The stock is 11% below its 20 day and 18% below its 50 day average. It is 44% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 40). The nearest support is the Pivot S1 at $0.81, and the nearest resistance the Pivot at $0.85.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 10.1%/day
Key levels
$1.8452 week high+119.0%
$1.21200 day average+44.0%
$1.15100 day average+36.9%
$0.9950 day average+17.9%
$0.9320 day average+10.7%
$0.92Swing high (Oct 16)+9.5%
$0.88Pivot R1+4.8%
$0.85Pivot+1.2%
$0.84Last close
$0.81Pivot S1−3.6%
$0.80Swing low (Oct 15)−4.8%
$0.7752 week low−8.3%
Indicators
RSI (14)39.97Weak, oversold below 30Neutral
MACD-0.02Below its signal lineBearish
Stochastic17.8Near the bottom of its rangeOversold
ADX (14)17.7No clear trend
Williams %R-92.6Oversold below −80, overbought above −20Oversold
CCI (20)-121.5Oversold below −100, overbought above 100Oversold
Rate of change−25.6%Change over 10 sessionsBearish
ATR (14)$0.09Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALLR

What happened before

See how ALLR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ALLR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ALLR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ALLR in the last 90 days.

Loading…

See today’s whale options flow across the market →

ALLR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●10 buying vs 10 selling
  • ▼Held by funds -1.2 pts
  • ▼Funds holding -1
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1920−5.0%
In funds' top 1000–
Held by funds6.8%8.0%−1.2 pts
New / increased5 / 58 / 3−9.1%
Reduced / sold out4 / 63 / 2+100.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALLR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLR is in one of them and how their past ALLR trades turned out.

ALLR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALLR in an article yet. Here's the latest on the wider market.

About Allarity Therapeutics

Allarity Therapeutics is a pharmaceutical company based in Boston, Massachusetts, that develops cancer treatments. Its main focus is stenoparib, a therapy being studied in ovarian cancer and small cell lung cancer. The company also develops its Drug Response Predictor platform, a companion diagnostic designed to identify which patients are most likely to benefit from a particular cancer drug.

Headquarters
Boston, MA